Posted by AGORACOM-JC
at 9:19 AM on Tuesday, January 19th, 2021
Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.
In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.
Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.
Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.
VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.
Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.
Posted by AGORACOM-JC
at 9:09 AM on Tuesday, January 19th, 2021
Announces Appointment of Dr. Jinyu Mo as Senior Vice President, Asia
Opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries.
TORONTO, Jan. 19, 2021 — POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries. She has over 22 years of experience spanning several companies, including MACOM Technology Solutions, Bookham/Oclaro, Huawei, I2R in Singapore and Nexvave Photonics Technology Co., which she founded and served as Chief Technology Officer. Dr. Mo was most recently with MACOM as the Senior Director and Chief Scientist of the Lightwave business unit in Asia and site leader in Shenzhen. Dr. Mo received her PhD degree in Optical Communications from Nanyang Technological University (NTU) Singapore. She is a Senior member of IEEE and has been a member of IEEE’s Technical Committees for several international conferences.
POET Optoelectronics Shenzhen Co. Ltd., a wholly foreign-owned enterprise (WFOE) and wholly-owned subsidiary of POET, will augment the Company’s existing design, development and engineering operations in Allentown, Pennsylvania and Singapore. The Shenzhen operation will also support the activities of Super Photonics Xiamen Co. Ltd., the Company’s joint venture with Sanan IC, a subsidiary of Sanan Optoelectronics Co., Ltd. (Shanghai Stock Exchange, SSE: 600703).
Posted by AGORACOM-JC
at 8:11 AM on Tuesday, January 19th, 2021
Access to up to 2,000 US Colleges and Universities with reach of up to 1.5 Million Students
Entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.
KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs.
The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.
TORONTO, ON / January 19, 2021/KABN Systems NA Holdings Corp. (CSE:KABN)(OTC PINK:TRWRF)(FRA:4T51) (the “Company“, “KABN North America” or “KABN NA“), a North American Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform, announces today that it has entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.
KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs. The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.
With reach to over 2,000 US College and University campuses and over 1.5 Million Gen Z students, alumni and families, The Campus Agency has been supporting innovative direct to student and online marketing programs for over 40 years.
“We’re excited to bring our 40 years of creating success on campus and digital initiatives to Liquid Avatar and to bring this important and innovative program to our collegiate communities, allowing users to manage and control their digital identity and future credentials safely and securely,” said Chris Nyland, Chief Operating Officer, The Campus Agency. “This is our second program with KABN North America and Liquid Avatar, as we’re already jointly a part of the COVID-19 consortium for creating Verifiable Identity Healthcare Credential.”
Posted by AGORACOM-JC
at 9:25 AM on Monday, January 18th, 2021
Announced today that the CEO of the Company, Cameron Chell, will be featured on “Making Money with Charles Payne” on Fox Business.
Segment on Fox Business will focus on Draganfly’s recent announcements in relation to Draganfly’s Varigard spraying program which provides 24-hour sequestration and kill efficacy against pathogens including COVID-19 in a single application.
Los Angeles, CA, Jan. 18, 2021 —Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“ Draganfly ” or the “ Company ”), an award-winning, industry-leading manufacturer and systems developer, announced today that the CEO of the Company, Cameron Chell, will be featured on “Making Money with Charles Payne” on Fox Business.
The segment on Fox Business will focus on Draganfly’s recent announcements in relation to Draganfly’s Varigard spraying program which provides 24-hour sequestration and kill efficacy against pathogens including COVID-19 in a single application.
“I am super excited to share our story with Charles Payne on Fox Business,” said Cameron Chell, CEO Draganfly. “The surface disinfecting market size is surging and expected to reach $1.5 billion by 2027, due in part to the requirement to disinfect large areas like stadiums. Varigard ™ has already established a technical leadership position and we look forward to providing the most advanced drones and services to their customers.”
Cameron Chell’s segment on Fox Business with Charles Payne will air at 2PM ET on Monday, January 18.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Posted by AGORACOM-JC
at 4:15 PM on Thursday, January 14th, 2021
Announced the successful completion of a large-scale production of exosomes
Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
This achievement is expected to pave the way for larger tests and studies.
Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.
“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.
Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
Posted by AGORACOM-JC
at 8:04 AM on Thursday, January 14th, 2021
Most of us know drones as cool toys flying around the neighbourhood, or perhaps even as simple commercial applications for things like real estate videos.
But the fact of the matter is that drone usage is about to go parabolic with huge corporations now testing ways to:
Use drones to provide Internet connections in remote locations.
Use drones to collect crowd data.
….. And there’s even a start-up that’s using drones to deliver tacos to your door.
In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones (hardware) to data … and one company is already ahead of the shift … DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)
DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:
Established in 1998 DFLY is considered the oldest commercial drone company in the world
Built the first drone that saved a life
Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
Detect infectious conditions in a person from a distance of 190 feet
Conduct phenotyping, data collection and analysis by the USDA
With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 3 drone companies in the world and why they have now begun the process of listing on NASDAQ.
If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or are just learning, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.
Posted by AGORACOM-JC
at 9:28 AM on Wednesday, January 13th, 2021
Announced that the Company has started the process of preparing for a listing of its common shares on the NASDAQ Capital Market
Company has engaged a New York based investment bank to begin the NASDAQ listing process.
The NASDAQ is a mark of achievement and stature for qualified companies.
Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
Los Angeles, CA., Jan. 13, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced that the Company has started the process of preparing for a listing of its common shares on the NASDAQ Capital Market (“NASDAQ”).
The Company has engaged a New York based investment bank to begin the NASDAQ listing process. The NASDAQ is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
The listing of the Company’s common shares on the NASDAQ is subject to the approval of the NASDAQ and the ability of the Company to satisfy all applicable listing and regulatory requirements. While the Company intends to satisfy all of the applicable listing criteria, there is no assurance that the NASDAQ will approve the Company’s application or that the Company will complete the listing as proposed.
Draganfly management believes up-listing to NASDAQ will:
Provide additional opportunities to attract institutional and retail investors, allowing the Company to broaden its investor base in the United States and internationally.
Increase the visibility of the Company, its growth strategy, accomplishments and results to date.
Embark on an aggressive M&A strategy.
Increase liquidity of the Company’s common shares; and
Raise the Company’s overall profile and ultimately enhance shareholder value.
“Today’s announcement is a significant milestone in our efforts to build Draganfly into an industry-leading manufacturer and systems developer,” said Cameron Chell, CEO of Draganfly. “In addition to increasing our visibility in the marketplace, the up-listing should improve the liquidity of our stock, broaden our institutional shareholder base and augment long-term shareholder value.”
Draganfly had significant growth in 2020 in regard to its customer acquisitions, partnerships, product development and the growth of the Company’s sales pipeline. Here are some highlights from the past twelve months:
Launched the Vital Intelligence Smart Vital COVID-19 assessment platform that can automatically detect elevated body temperature and, with voluntary consent, heart rate, respiratory rate and O2 saturation, all from a camera that takes seconds to capture the information.
Launched a telehealth app for third party developers to integrate the Smart Vital technology with their own apps and devices.
Achieved 200%+ year-over-year revenue growth with 50% quarter-over-quarter revenue growth in the third quarter (1) ;
Launched two additional flight services divisions in the mining and facility management industries (which includes providing the delivery via Draganfly’s patented drone technologies of the Varigard pathogen and virus surface sanitizer);
Exclusive worldwide distributor of Aerovironment’s (NASDAQ: AVAV) Quantix Mapper RPAS;
Selected by Coldchain Technology Services, LLC to immediately develop and provide flight services of a robust vaccine delivery payload for use in critical regions for drone delivery of the COVID-19 vaccine; and
Awarded new patent for a vertical take-off and landing (VTOL) cargo delivery drone with variable center of gravity.
